CORE
🇺🇦
make metadata, not war
Services
Services overview
Explore all CORE services
Access to raw data
API
Dataset
FastSync
Content discovery
Recommender
Discovery
OAI identifiers
OAI Resolver
Managing content
Dashboard
Bespoke contracts
Consultancy services
Support us
Support us
Membership
Sponsorship
Community governance
Advisory Board
Board of supporters
Research network
About
About us
Our mission
Team
Blog
FAQs
Contact us
A phase I study of nolatrexed dihydrochloride in children with advanced cancer. A United Kingdom Children's Cancer Study Group Investigation
Authors
S Ablett
A V Boddy
+16 more
M Brampton
N Clendeninn
E J Estlin
R Hobson
A Johnston
J Kohler
L Lashford
I J Lewis
H McDowell
B Morland
D R Newell
A D J Pearson
C R Pinkerton
M Pitsiladis
L Price
G A Taylor
Publication date
1 January 2001
Publisher
Nature Publishing Group
Doi
Cite
View
on
PubMed
Abstract
A phase I study of nolatrexed, administered as a continuous 5 day intravenous infusion every 28 days, has been undertaken for children with advanced malignancy. 16 patients were treated at 3 dose levels; 420, 640 and 768 mg/m2 24 h−1. 8 patients were evaluable for toxicity. In the 6 patients treated at 768 mg/m2 24 h−1, dose-limiting oral mucositis and myelosuppression were observed. Plasma nolatrexed concentrations and systemic exposure, measured in 14 patients, were dose related, with mean AUC values of 36 mg−1 ml−1 min−1, 50 mg ml−1 min−1 and 80 mg ml−1 min−1at the 3 dose levels studied. Whereas no toxicity was encountered if the nolatrexed AUC was <45 mg ml−1 min−1, Grade 3 or 4 toxicity was observed with AUC values of >60 mg ml−1 min−1. Elevated plasma deoxyuridine levels, measured as a surrogate marker of thymidylate synthase inhibition, were seen at all of the dose levels studied. One patient with a spinal primitive neuroectodermal tumour had stable disease for 11 cycles of therapy, and in two patients with acute lymphoblastic leukaemia a short-lived 50% reduction in peripheral lymphoblast counts was observed. Nolatrexed can be safely administered to children with cancer, and there is evidence of therapeutic activity as well as antiproliferative toxicity. Phase II studies of nolatrexed in children at the maximum tolerated dose of 640 mg/m2 24 h−1are warranted. © 2001 Cancer Research Campaign http://www.bjcancer.co
Similar works
Full text
Open in the Core reader
Download PDF
Available Versions
University of Queensland eSpace
See this paper in CORE
Go to the repository landing page
Download from data provider
oai:espace.library.uq.edu.au:U...
Last time updated on 04/08/2016
University of Birmingham Research Portal
See this paper in CORE
Go to the repository landing page
Download from data provider
oai:pure.atira.dk:openaire_cri...
Last time updated on 14/12/2019
University of Birmingham Research Portal
See this paper in CORE
Go to the repository landing page
Download from data provider
oai:pure.atira.dk:publications...
Last time updated on 01/02/2019
Crossref
See this paper in CORE
Go to the repository landing page
Download from data provider
Last time updated on 05/06/2019